{"id":9277,"date":"2025-11-27T21:23:47","date_gmt":"2025-11-27T18:23:47","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9277"},"modified":"2025-11-27T21:23:47","modified_gmt":"2025-11-27T18:23:47","slug":"aha-2025-pcsk9-inhibitors-enlicitide-oral-pcsk9i","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/aha-2025-pcsk9-inhibitors-enlicitide-oral-pcsk9i\/","title":{"rendered":"AHA 2025 \u2013 PCSK9 Inhibitors &#038; Enlicitide (Oral PCSK9i)"},"content":{"rendered":"<div>AHA 2025 \u2013 PCSK9 Inhibitors &amp; Enlicitide (Oral PCSK9i)<\/div>\n<div><\/div>\n<div>Source: theheart.org on Medscape \u2014 Nov 24, 2025<\/div>\n<div><span> 1. VESALIUS-CV: Evolocumab lowered MACE in high-risk primary-prevention patients, with signals of reduced mortality.<\/span><\/div>\n<div><span> 2. LDL principle: Lower LDL-C consistently reduces events across all risk levels \u2014 no real primary vs secondary separation.<\/span><\/div>\n<div><span> 3. Underuse: PCSK9 inhibitors remain rarely prescribed despite improved access and low cost; injections and clinic time are major barriers.<\/span><\/div>\n<div><span> 4. Enlicitide (oral PCSK9i): Phase 3 shows LDL-C reduction equal to monoclonal antibodies with strong adherence and excellent safety.<\/span><\/div>\n<div><span> 5. Combination therapy: Target-based LDL-C management is preferred; stepwise escalation often fails for patients far from goal.<\/span><\/div>\n<div><span> 6. Add-on options:<\/span><\/div>\n<div><span> \u2022 Some very high-risk patients may require triple therapy (statin + ezetimibe + a third agent).<\/span><\/div>\n<div><span> \u2022 Quadruple therapy is possible when LDL-C remains high: statin + ezetimibe + PCSK9 inhibitor + bempedoic acid.<\/span><\/div>\n<div><span> 7. Outlook: Oral therapy may reduce inertia, expand use, accelerate reaching LDL-C targets, and potentially lower costs.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.medscape.com\/viewarticle\/time-overcome-pcsk9i-inertia-new-data-future-options-2025a1000wf8?utm_source=chatgpt.com\">https:\/\/www.medscape.com\/viewarticle\/time-overcome-pcsk9i-inertia-new-data-future-options-2025a1000wf8?utm_source=chatgpt.com<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AHA 2025 \u2013 PCSK9 Inhibitors &amp; Enlicitide (Oral PCSK9i) Source: theheart.org on Medscape \u2014 Nov 24, 2025 1. VESALIUS-CV: Evolocumab lowered MACE in high-risk primary-prevention patients, with signals of reduced mortality. 2. LDL principle: Lower LDL-C consistently reduces events across all risk levels \u2014 no real primary vs secondary separation. 3. Underuse: PCSK9 inhibitors remain [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9277","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9277"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9277\/revisions"}],"predecessor-version":[{"id":9278,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9277\/revisions\/9278"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}